CX3CR1 and pulmonary arterial hypertension: Our study suggests that the inhibition of CX3CR1 expression could be a potential strategy for hypoxia-induced lung disease treatment, and also, to some extent, the activation of innate immunity such as macrophage polarization might be an effective therapeutic target towards PAH disease.